The incidence and mortality of small-cell lung cancer worldwide make this disease a notable
health-care issue. Diagnosis relies on histology, with the use of immunohistochemical …

… We examined the prevalence of and risk factors for gefitinib-induced ILD associated with
practical use of the drug in Japanese with non–small-cell lung cancer (NSCLC). Patients and …

… Lung cancer is the leading cause of cancer mortality worldwide… Lung cancer, including all
histological subtypes, is more … As with lung cancer in general, SCLC is most prevalent in men …

… The vast majority, more than 95%, of these patients develop small-cell lung cancer because
of tobacco smoking. The risk of developing the cancer increases both with the number of …

… Microsatellite alterations in 50% of primary small cell lung carcinoma (SCLC) have been …
DNA of cancer patients, we looked for microsatellite alterations in the plasma of SCLC patients. …

… Lung cancer (LC) is the leading cause of cancer death in the United States.1 Nonsmall cell
lung cancer (NSCLC) accounts for 80% to 85% of LC. Patients with early stage NSCLC have …

… Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical
trial… A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J …

… patients with resected stage I nonsmall cell lung cancer (NSCLC). Using data from the California
Cancer … on survival in patients with stage I NSCLC to identify a subset of patients at high …

… assays such as PD-L1 assay in 2 patients, PIK3CA assay in one patient, EML4-ALK assay
was in 2 patients, transformation to small cell lung cancer in 12 patients. For the remaining 4 …

… The results of this study suggest that for non-small cell lung cancer patients, the dose to
achieve significant probability of tumor control (>50%) may be large (on the order of 84 Gy) to …